Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
Biomea Fusion, Inc. (BMEA)
Company Research
Source: GlobeNewswire
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapyTopline 26-week primary endpoint data from both Phase II studies anticipated 4Q 2026 SAN CARLOS, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that the first patient has been dosed in its newly initiated Phase II programs, COVALENT-211 and COVALENT-212, evaluating icovamenib in patients with type 2 diabetes (“T2D”), marking a key step in advancing icovamenib into Phase II development in targeted patient populations failing standard-of-care therapies as established in the clinical trial COVALENT-111. “These studies represent an important step forward as we advance icovamenib into later-stage Phase II development in the two clearly defined patient
Show less
Read more
Impact Snapshot
Event Time:
BMEA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMEA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMEA alerts
High impacting Biomea Fusion, Inc. news events
Weekly update
A roundup of the hottest topics
BMEA
News
- Biomea Fusion (BMEA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $12.00 price target on the stock.MarketBeat
- Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies [Yahoo! Finance]Yahoo! Finance
- Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts [Yahoo! Finance]Yahoo! Finance
- Biomea Fusion (BMEA) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BMEA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "MarketBeat
- Biomea Fusion (BMEA) had its price target raised by Citigroup Inc. from $6.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
BMEA
Earnings
- 11/4/25 - Miss
BMEA
Sec Filings
- 4/3/26 - Form 4
- 4/3/26 - Form 4
- 3/24/26 - Form 10-K
- BMEA's page on the SEC website